VIRAL LOAD. RESISTANCE. IMMUNITY.

CMV Testing

Partner with a laboratory known for excellence in science, exceptional service, multiple accepted specimen types, fast TAT and a comprehensive CMV test menu to manage your most critical patients.

Complete CMV diagnostics to improve patient outcomes:

1. Early Detection of CMV Reactivation, Primary Infections
2. Monitor Response to Treatment
3. Confirm Antiviral Resistance
4. Establish Immunity

Benefits of working with Eurofins Viracor:

Industry leading turnaround time for all of our CMV Assays
Assay refinement using dual targets, multiple probes and mutation surveillance ensures your patient will be evaluated using the most up-to-date and accurate testing
Ability to send all of your CMV testing to one lab:
- PCR viral load for adults and neonates
- Drug Resistance, now including FDA-approved maribavir (LIVTENCITY™)
- T Cell Immunity, which uniquely evaluates CD4 and CD8 T cells
Multiple specimen types accepted for ease of collection

CMV inSIGHT™ T Cell Immunity

CMV Antiviral Resistance

CMV Diagnostics Video

Visit The CMV Test Menu

CMV Testing for Transplant & Immunocompromised Patients

	Test Name	Test Code	Turnaround Time & Test Details
PCR / Viral Load	CMV Real-time Quantitative PCR	5500	Same day (within 8-12 hours from receipt of specimen) Most specimen types offer quantitative results Over 19 specimen types
PCR / Viral Load	CMV Saliva Real-time PCR	5571	Same day (within 8-12 hours from receipt of specimen) Saliva samples are simple, noninvasive, and easy to collect for congenital CMV detection Sample collection within 21 days after baby is born to confirm diagnosis
Resistance	NEW CMV Resistance: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir	33125	Within 2-4 days of receipt of specimen (often reported in just 2.5 days) Plasma specimen type DNA viral load must be above 1000 uL/mL to run—one of the lowest minimum viral loads in the industry
	NEW CMV Resistance: Maribavir, Ganciclovir, Foscarnet, Cidofovir	33126
	CMV Resistance: Letermovir	30722
Immunity	CMV inSIGHT™ T Cell Immunity Panel	30360	2-3 days from receipt of specimen Whole Blood in sodium heparin Live Cell tests have special collection and shipping requirements

Innovations in CMV Immunity

CMV inSIGHT™ T Cell Immunity Assay

Assess current immune response for viral target
Confirm if virus specific CD4 and CD8 T Cells are present
Evaluate treatment decisions

CMV T Cell Immunity Test

WHITE PAPER

Evaluating Cytomegalovirus Cell Mediated Immunity Diagnostic Assays

Explore data on various CMV cell mediated immunity assays and how they can potentially benefit your immunocompromised patients.

inSIGHT™ T Cell Immunity

Optimizing CMV Outcomes

Viracor can make it easier for healthcare providers to manage CMV patients with testing options spanning the continuum of care.

Baseline & Monitor Viral Load

Quantitative CMV PCR can be used for early detection of reactivation, primary infection and monitoring response to treatment.

Dual gene targets and multiple probes increases the assay’s ability to pick up polymorphisms, therefore reducing the chance for false negatives and detecting other strains that could otherwise be missed.

Learn More

Confirm Antiviral Resistance

Patient outcomes depend on effective prophylaxis and treatment with antiviral therapies, including ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir, and maribavir.

Laboratory testing should be used to confirm drug resistance, as treatment modification based solely on clinical suspicion may result in added toxicity and increased complexity in patient management.

Learn More

Establish Immunity

The CMV T Cell Immunity Panel measures the strength of T cell responses to CMV-specific antigens and reports the activity of CD4 and CD8 T cell responses independently.

Evaluating immunocompromised patients’ CMV-specific T cell response will help healthcare providers decide when to take patients off of antiviral medication during critical stages in treatment.

Learn More

Watch how Viracor's CMV T Cell Immunity Panel Helps A Post-Transplant CMV Treatment Plan

Understand how your patient's immune system is responding to CMV medication.

References

¹ Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. Apr 15 2010;89(7):779-95.

² Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711-9.

Explore By Category